Press Release

December 9 2025

Verismo Therapeutics Shares Positive Preclinical Data at ASH 2025 Comparing SynKIR™-310 With Conventional CAR-T

MORE >

November 10 2025

Verismo Therapeutics Presents Promising Preclinical Data at SITC 2025 for SynKIR™-110 in Solid Tumors

MORE >

November 5 2025

Verismo Therapeutics to Announce Upcoming Presentations at SITC and ASH Annual Meetings

MORE >

October 23 2025

Verismo Therapeutics to Present at iMig 2025

MORE >

October 2 2025

Verismo Therapeutics Treats First Follicular Lymphoma Patient in CELESTIAL-301 Trial, Strengthening Collaboration with IFLI

MORE >

September 25 2025

Verismo Therapeutics Announces Partnership with Miltenyi Biotec to Support Advancing Clinical Programs

MORE >

July 29 2025

Verismo Therapeutics Named One of Philadelphia Business Journal’s 2025 Best Places to Work for Third Consecutive Year

MORE >

May 23 2025

Verismo Therapeutics Provides Updates on Upcoming Poster Presentation at ASCO 2025

MORE >

April 24 2025

Verismo Therapeutics Announces Poster Presentation at ASCO 2025

MORE >

January 10 2025

Verismo Therapeutics Announces First Patient Infused in Phase 1 CELESTIAL-301 Clinical Trial of SynKIR™-310

MORE >